Bayer AG

In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.

In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.

Demand for Zoetis’ products is driven by a growing population coupled with a rising middle class in emerging markets and increased relocation from rural to urban areas.

Faced with expiring patents and increasing competition for its blockbuster drugs, Amgen acquired Onyx to benefit from the latter’s innovative oncology portfolio and pipeline.

On September 13, Sanofi announced a change in two of its GBUs to enable focused operations across emerging markets and mature markets.

In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx.

In 4Q17, Merck’s Zetia reported revenues of $323 million, which was ~44% lower on a year-over-year basis and a 1% rise on a quarter-over-quarter basis.

Pfizer’s (PFE) Peri-LOE products refer to those products that lost patient protection recently or are expected to lose patient protection soon.

In the US and international markets in 4Q17, Sutent generated revenues of $96 million and $180 million, respectively.

In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.

In 4Q17, Biogen’s (BIIB) interferons generated revenues of $645 million, which reflected a 6% decline YoY and a 3% decline on a quarter-over-quarter basis.

In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.

Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.

In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.

In 3Q17, in the US and outside the US (international markets), JNJ’s pulmonary hypertension portfolio generated revenues of $357 million and $283 million, respectively.

In 3Q17, Johnson & Johnson’s (JNJ) oral care products generated revenues of $382 million, which reflected a 3% decline quarter-over-quarter.

In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.

In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.

After success in the company’s phase 1/2 trial with BMN 270, an investigational gene therapy for hemophilia A, BioMarin Pharmaceuticals (BMRN) is expected to start phase 3 trials.

In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.

In 2Q17, Chantix/Champix generated revenues of ~$248 million, which represents ~16% growth on a YoY basis and 4% growth on a quarter-over-quarter basis.

In 2Q17, United Therapeutics’ (UTHR) Unituxin generated revenues of around $16 million, a 10% decline on a year-over-year (or YoY) basis and an 11% decline on a quarter-over-quarter basis.

Vectibix’s revenue trends In 2Q17, Amgen’s (AMGN) Vectibix generated revenues of ~$168 million, which represented a ~5% YoY (year-over-year) rise and a ~14% QoQ (quarter-over-quarter) rise. In the US, Vectibix generated revenues of ~$62 million in 2Q17, or ~19% higher YoY. Outside the US, Vectibix reported revenues of ~$106 million, or 2% lower YoY and […]

In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.

In 2016, Pfizer’s (PFE) Chantix reported revenues of ~$842 million, which represents a ~25% YoY (year-over-year) rise.

In 2016, Merck’s (MRK) Animal Health segment reported revenues of ~$3.5 billion, which reflected ~4% growth year-over-year.

The Columbia European Equity Fund Class A (AXEAX) invests in “equity securities of European companies that are believed to offer growth potential.”

AXEAX was invested across 69 holdings as of March 2016, seven more than a quarter ago. It was managing assets worth $515.6 million as of March.

From a purely NAV (net asset value) return standpoint, the USIFX did not have a notable showing in either the one-year period until February 29, 2016, or in 2015.

The Artisan International Fund – Investor Class (ARTIX) has been in existence since December 1995.

As of the September portfolio of the Columbia European Equity Fund, the top ten equity holdings included Novartis, Roche Holding, and Prudential Financial.

The Artisan International Fund (ARTIX) requires a minimum initial investment of $1,000. There’s no minimum or specific amount needed to add to an account.

The Columbia European Equity Fund seeks capital appreciation by investing in “equity securities of European companies that…offer growth potential.”